What Should I Do If My Respiratory Panel is Positive?
After a positive respiratory pathogen is identified via a multiplex respiratory PCR panel test, the focus shifts to data validation and clinical reporting. This guide outlines the essential laboratory workflows required to translate raw analytical data into actionable diagnostic insights while maintaining stringent bio‑safety standards. At BP LabLine, we support clinical labs with reliable molecular diagnostics tools that integrate seamlessly into post‑positive workflows.
Step 1: Data Validation and Quality Control
A positive result from a respiratory panel test (e.g., detecting SARS‑CoV‑2, influenza A/B, RSV, or other pathogens) must first undergo rigorous data validation. Laboratory staff should review internal amplification controls, cycle threshold (Ct) values, and any signs of cross‑contamination or reagent carryover. If the Ct value is near the assay’s limit of detection, a repeat test from the original sample is recommended to rule out false positives. At BP LabLine, our respiratory PCR panel tests are designed with built‑in quality control features, including positive and negative controls in every run, to help labs quickly confirm true positives.
Step 2: Bio‑safety and Sample Handling
Once a positive result is validated, all remaining biological samples and any materials exposed to the sample must be handled as potentially infectious. Adhere to local biosafety level (BSL‑2 or higher) guidelines: use sealed containers for transport, decontaminate work surfaces with appropriate disinfectants, and autoclave waste before disposal. If the panel identifies a notifiable pathogen (e.g., novel influenza or MERS‑CoV), immediate notification of the local public health authority is required. BP LabLine provides detailed biosafety protocols for laboratories using our multiplex PCR kits, ensuring compliance with WHO and CDC recommendations.
Step 3: Clinical Reporting and Interpretation
The validated positive result must be translated into a clear, actionable clinical report. The report should include:
The specific pathogen(s) detected (e.g., “Respiratory syncytial virus A”),
Semi‑quantitative information (e.g., Ct value range: low/medium/high),
Reference ranges and interpretation guidelines,
A disclaimer that results should be correlated with clinical presentation.
Labs should use a Laboratory Information System (LIS) to auto‑populate data and reduce transcription errors. BP LabLine’s respiratory panel test software supports direct LIS integration, allowing seamless transfer of validated results into patient records.
Step 4: Communication and Follow‑Up
Positive results must be communicated promptly to the ordering clinician or public health authority. For high‑consequence pathogens, many jurisdictions require immediate telephone notification before electronic release. The laboratory should also provide guidance on recommended confirmatory testing (e.g., viral culture for novel pathogens) or antimicrobial susceptibility testing if a bacterial pathogen is identified. BP LabLine offers technical support to help labs establish clear algorithms for result communication and escalation.
Conclusion
A positive result on a respiratory panel test is not the end of the analytical process—it is the beginning of a critical chain of data validation, biosafety management, and accurate clinical reporting. By following standardised workflows for quality control, sample handling, LIS integration, and timely communication, laboratories can turn a raw positive signal into a reliable diagnostic report. BP LabLine remains committed to providing high‑quality multiplex PCR panels and implementation support, helping labs maintain safety, accuracy, and regulatory compliance in every positive case.
